JP2024016177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016177A5 JP2024016177A5 JP2023189493A JP2023189493A JP2024016177A5 JP 2024016177 A5 JP2024016177 A5 JP 2024016177A5 JP 2023189493 A JP2023189493 A JP 2023189493A JP 2023189493 A JP2023189493 A JP 2023189493A JP 2024016177 A5 JP2024016177 A5 JP 2024016177A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- formulation according
- formulation
- tigit antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 28
- 229920001213 Polysorbate 20 Polymers 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 8
- 229940068977 polysorbate 20 Drugs 0.000 claims 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 7
- 229930195722 L-methionine Natural products 0.000 claims 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 7
- 229960004452 methionine Drugs 0.000 claims 7
- 239000007974 sodium acetate buffer Substances 0.000 claims 7
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000037581 Persistent Infection Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 102100035355 Cadherin-related family member 3 Human genes 0.000 claims 1
- 101000737802 Homo sapiens Cadherin-related family member 3 Proteins 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500278P | 2017-05-02 | 2017-05-02 | |
| US62/500,278 | 2017-05-02 | ||
| JP2019559836A JP7402693B2 (ja) | 2017-05-02 | 2018-05-01 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| PCT/US2018/030516 WO2018204405A1 (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559836A Division JP7402693B2 (ja) | 2017-05-02 | 2018-05-01 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016177A JP2024016177A (ja) | 2024-02-06 |
| JP2024016177A5 true JP2024016177A5 (https=) | 2024-06-17 |
Family
ID=64016405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559836A Active JP7402693B2 (ja) | 2017-05-02 | 2018-05-01 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| JP2023189493A Pending JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559836A Active JP7402693B2 (ja) | 2017-05-02 | 2018-05-01 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200354453A1 (https=) |
| EP (1) | EP3618855A4 (https=) |
| JP (2) | JP7402693B2 (https=) |
| KR (1) | KR102770786B1 (https=) |
| CN (1) | CN110603052A (https=) |
| AU (1) | AU2018261080A1 (https=) |
| BR (1) | BR112019022698A2 (https=) |
| CA (1) | CA3061050A1 (https=) |
| CL (1) | CL2019003145A1 (https=) |
| CO (1) | CO2019012356A2 (https=) |
| IL (1) | IL270175B2 (https=) |
| MA (1) | MA50661A (https=) |
| MX (1) | MX2019013033A (https=) |
| SG (2) | SG10202111905PA (https=) |
| WO (1) | WO2018204405A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN108290936B (zh) * | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| KR20210104736A (ko) * | 2018-12-14 | 2021-08-25 | 모르포시스 아게 | 항체 제형 |
| KR102332847B1 (ko) * | 2019-06-13 | 2021-12-01 | 주식회사 녹십자 | Tigit에 대한 항체 및 이의 용도 |
| US20220273796A1 (en) * | 2019-07-19 | 2022-09-01 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| CN115052622B (zh) * | 2020-01-21 | 2026-03-06 | 夏尔巴生物技术(杭州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
| JP7674369B2 (ja) * | 2020-01-24 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 安定な抗体製剤 |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| MX2022015157A (es) * | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| US20240067720A1 (en) * | 2021-01-14 | 2024-02-29 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibody pharmaceutical composition and application thereof |
| AU2022212007A1 (en) | 2021-01-29 | 2023-09-07 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| IL310217A (en) * | 2021-07-23 | 2024-03-01 | Akeso Biopharma Inc | Pharmaceutical composition and use |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN114106182B (zh) * | 2022-01-26 | 2022-05-17 | 中山康方生物医药有限公司 | 抗tigit的抗体及其用途 |
| EP4482868A4 (en) * | 2022-02-24 | 2026-03-04 | Merck Sharp & Dohme Llc | STABLE FORMULATIONS OF A MULTIVALENT, VHH-BASED, CYTOTOXIC, T-LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) BINDING TO HUMANE CTLA4, AND METHOD FOR USE THEREMISSION |
| CN119173272A (zh) * | 2022-04-14 | 2024-12-20 | 百济神州瑞士有限责任公司 | 含有pd-1抗体的稳定高浓度精氨酸配制品及其使用方法 |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| US20250362305A1 (en) * | 2022-08-04 | 2025-11-27 | Merck Sharp & Dohme Llc | Methods for determining one or more critical quality attributes of co-formulated antibodies |
| CN120569213A (zh) * | 2022-12-27 | 2025-08-29 | 上海复宏汉霖生物技术股份有限公司 | 包含抗tigit抗体的药物制剂 |
| WO2025166550A1 (zh) * | 2024-02-06 | 2025-08-14 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
| WO2025248110A1 (en) | 2024-05-31 | 2025-12-04 | Replimune Limited | An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200831129A (en) * | 2006-10-06 | 2008-08-01 | Amgen Inc | Stable formulations |
| CA2765220A1 (en) * | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| PT2691112T (pt) * | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| BR112016000853A2 (pt) * | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| MD4733C1 (ro) * | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| EP3349792A1 (en) | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
| WO2017112621A1 (en) * | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Formulations of engineered anti-il-10 antibodies |
| WO2017189433A1 (en) * | 2016-04-25 | 2017-11-02 | Medimmune, Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
-
2018
- 2018-05-01 KR KR1020197035375A patent/KR102770786B1/ko active Active
- 2018-05-01 MX MX2019013033A patent/MX2019013033A/es unknown
- 2018-05-01 EP EP18793797.4A patent/EP3618855A4/en active Pending
- 2018-05-01 BR BR112019022698A patent/BR112019022698A2/pt unknown
- 2018-05-01 WO PCT/US2018/030516 patent/WO2018204405A1/en not_active Ceased
- 2018-05-01 US US16/610,188 patent/US20200354453A1/en not_active Abandoned
- 2018-05-01 AU AU2018261080A patent/AU2018261080A1/en not_active Abandoned
- 2018-05-01 MA MA050661A patent/MA50661A/fr unknown
- 2018-05-01 CA CA3061050A patent/CA3061050A1/en active Pending
- 2018-05-01 CN CN201880029167.7A patent/CN110603052A/zh active Pending
- 2018-05-01 SG SG10202111905PA patent/SG10202111905PA/en unknown
- 2018-05-01 SG SG11201909941Q patent/SG11201909941QA/en unknown
- 2018-05-01 IL IL270175A patent/IL270175B2/en unknown
- 2018-05-01 JP JP2019559836A patent/JP7402693B2/ja active Active
-
2019
- 2019-10-30 CL CL2019003145A patent/CL2019003145A1/es unknown
- 2019-11-01 CO CONC2019/0012356A patent/CO2019012356A2/es unknown
-
2023
- 2023-11-06 JP JP2023189493A patent/JP2024016177A/ja active Pending
-
2024
- 2024-01-25 US US18/422,352 patent/US20240182573A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016177A5 (https=) | ||
| JP2020518600A5 (https=) | ||
| JP2023109942A5 (https=) | ||
| US20240182573A1 (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2020518598A5 (https=) | ||
| JP2024102215A5 (https=) | ||
| JP2023515271A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| KR102031020B1 (ko) | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 | |
| JP2020516240A5 (https=) | ||
| CN119679936A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| AU2018263837A1 (en) | Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| JP2022532927A5 (https=) | ||
| JP2020509031A5 (https=) | ||
| JP2016533335A5 (https=) | ||
| HRP20250666T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| RU2012131099A (ru) | Препарат антитела | |
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| JP2020158505A5 (https=) | ||
| RU2020112280A (ru) | Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение | |
| JP2024518536A5 (https=) | ||
| CN112007162A (zh) | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 | |
| WO2024183643A1 (zh) | 含抗tim-3抗体的药物组合 |